AstraZeneca Pharma India Ltd. — Earnings Release 2026

Aug 14, 2025

==> picture [503 x 53] intentionally omitted <==

August 14, 2025

The Manager – Listing BSE Limited 1[st] Floor, New Trading Ring Rotunda Building, P J Towers, Dalal Street, Fort, Mumbai 400001

The Manager – Listing National Stock Exchange of India Ltd. Exchange Plaza, 5[th] Floor, Plot No. C/1, G Block Bandra-Kurla Complex, Bandra (E), Mumbai 400051

Dear Sir(s),

Sub: Press Release

Ref: Scrip Code - BSE: 506820 / NSE: ASTRAZEN

Please find enclosed the press release for the unaudited financial results for the quarter ended June 30, 2025.

Thanking you,

For AstraZeneca Pharma India Limited

Digitally signed MANAS by MANASA RAMA A RAMA Date: 2025.08.14 17:40:27 +05'30'

Manasa. R Company Secretary

==> picture [452 x 64] intentionally omitted <==

News Release

==> picture [111 x 36] intentionally omitted <==

AstraZeneca Pharma India Limited Sustains Growth Momentum in Q1 FY25-26, Advancing Performance Across Diverse Therapies

Revenue rises 36% in Q1 2025-26; four new approvals reinforce leadership in Oncology

Bengaluru, August 14, 2025: AstraZeneca Pharma India Limited (the Company), a science-led biopharmaceu�cal company, today announced its financial results for the quarter ended June 30, 2025. Demonstra�ng consistent growth across therapy areas, the Company reported a revenue increase of 36% compared to the same period last year, supported by strategic execu�on, regulatory milestones, and con�nued por�olio expansion.

Financial performance Summary:

==> picture [464 x 198] intentionally omitted <==

----- Start of picture text -----

Summary Q1 2025 Q1 2024
Apr -Jun’25 Apr -Jun’24
(Value in INR Mn) (Value in INR Mn)
Total Revenue from Opera�on 5263.1 3,875.2
Profit before excep�onal item and 750.6 424.0
tax
Profit a�er excep�onal item and tax 558.3 (117.9)
TA-wise performance Oncology 3702.7 2,394.2
Biopharmaceu�cals 1183.2 1,263.3
(CVRM, R&I and V&I)
Rare Disease 4.2 2.1
----- End of picture text -----

, said, “Our strong Q1 performance reflects the power of science-led innova�on combined with disciplined execu�on. Each regulatory milestone brings us closer to transforming outcomes for pa�ents living with chronic diseases. We remain focused on expanding our por�olio, strengthening partnerships, and ensuring that breakthrough medicines reach the people who need them most.”

Praveen Rao Akkinepally, Country President & Managing Director, said , “Delivering consistent growth across therapy areas reaffirms the strength of our Growth Through Innova�on strategy and the passion of our teams to help more pa�ents. At AstraZeneca, we are guided by a bold ambi�on to transform pa�ent outcomes by delivering the right treatment at the right �me. These results are a testament to what is possible when science, and purpose come together.”

News Release

==> picture [111 x 36] intentionally omitted <==

Key milestones:

• Received Central Drugs Standard Control Organisa�on (CDSCO) approval to import for sale and for distribu�on of Osimer�nib tablets for an addi�onal indica�on in in combina�on with pemetrexed and pla�num-based chemotherapy for the first-line treatment of pa�ents with locally advanced or metasta�c non-small cell lung cancer (NSCLC) whose tumours have EGFR exon 19 dele�ons or exon 21 (L858R) subs�tu�on muta�ons

• Received CDSCO approval to import for sale and for distribu�on of trastuzumab deruxtecan for addi�onal indica�on in HER2-low and HER2-ultralow metasta�c breast cancer pa�ents, who have received at least one endocrine therapy in metasta�c se�ng.

• Gained CDSCO approval for addi�onal indica�on of Osimer�nib as a monotherapy, for import for sale and for distribu�on for the treatment of pa�ents with locally advanced, unresectable (stage III) NSCLC whose tumours have EGFR exon 19 dele�ons or exon 21 (L858R) subs�tu�on muta�ons and whose disease has not progressed during or following pla�num based chemoradia�on therapy.

• Through the CDSCO approval received for import for sale and for distribu�on of Benralizumab, it was for addi�onal indica�on as an add-on treatment for adult pa�ents with relapsing or refractory eosinophilic granulomatosis with polyangii�s (EGPA).

Recogni�ons:

•  1st Place in 2025 SAS Customer Recogni�on Awards for innova�ve use of Real-World Data in clinical trials.

• Featured by Fortune India as a leading mul�na�onal transforming healthcare in India.

About AstraZeneca Pharma India Ltd

AstraZeneca is a global, science-led biopharmaceu�cal company that focuses on the discovery, development and commercialisa�on of prescrip�on medicines, primarily for the treatment of diseases in four therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory and Rare Disease. AstraZeneca operates in over 100 countries and its innova�ve medicines are used by millions of pa�ents worldwide. Comple�ng its 45 years in India, AstraZeneca Pharma India Limited is headquartered at Bengaluru, Karnataka in India and has a workforce of over 600 employees across the country commi�ed to deliver great medicines to pa�ents through innova�ve science and global excellence in development and commercializa�on. For more informa�on, please visit our website: h�ps://www.astrazeneca.in/ or follow us on LinkedIn: AstraZeneca India.